CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nextgen Biomed Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nextgen Biomed Ltd
Oppenheimer 7
Phone: +972 33742282p:+972 33742282 REHOVOT, 7670107  Israel Ticker: NXGN-MNXGN-M
This company was Merged or Acquired on 8/3/2011.
This is a Subsidiary, click here for the Parent Company
Business Summary
Nextgen Biomed Ltd. is an Israel-based medical technology and biotechnology company focused on diabetes management, medical devices, and clinical diagnostics. The Company develops EyePen, a smart device designed to assist diabetes patients in monitoring insulin usage and injection timing. Through its subsidiary Sentak Medical Technologies Ltd., the Company develops diagnostic technologies based on the detection and analysis of biological markers, including volatile organic compounds and breath-based diagnostics. Its activities include the development of medical devices, diagnostic platforms, healthcare technologies, and disease-monitoring solutions designed to support disease management, clinical diagnostics, and early detection applications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JacobAmidror
Chief Executive Officer, Director YanivHevron
Chief Financial Officer OrenAttiya
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Nextgen Biomed Ltd
NXGN
NXGN-M
Sela Group.Com Ltd.
Sindolor Holdings Ltd.
Sindolor Medical Ltd.

General Information
Number of Employees: 187 (As of 3/31/2010)
Outstanding Shares: 22,476,072 (As of 8/27/2026)
Stock Exchange: TLV
Fax Number: +972 98849441


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, September 27, 2026